Feb. 16, 2005 — The U.S. Food and Drug Administration (FDA) approved in November 2004 revisions to safety labeling to advise healthcare professionals of the following changes: glycopyrrolate ...

King Pharmaceuticals and Wyeth have amended and restated their co-promotion agreement for King’s Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor to treat high blood pressure.

King Pharmaceuticals has launched a tablet formulation of Altace (ramipril). The tablets will be available in 1.25mg, 2.5mg, 5mg, and 10mg dosage strengths and are indicated for the treatment of ...

One-Third of Surveyed Payers Identify Altace as the Most Efficacious Therapy for Diabetic Nephropathy, According to Findings from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision ...

Nov. 11, 2005 — The U.S. Food and Drug Administration (FDA) has approved first-time generic formulations of glimepiride 1-, 2-, and 4-mg tablets and first-time doses of 3-, 6-, and 8-mg tablets for ...

NEW YORK, Sept 12 (Reuters) - King Pharmaceuticals Inc said on Wednesday it would seek a rehearing with the U.S. federal appeals court that ruled the patent on King's biggest product, high blood ...

A federal appeals court has reversed a decision made by the U.S. District Court for the Eastern District of Virginia, which had found that Lupin Pharmaceuticals had infringed on a compound patent of ...

US drug giant Wyeth has decided to close the curtains on its deal to co-market King Pharmaceutical’s flagship hypertension drug, Altace. The company is planning to return all rights to King in January ...

NEW YORK, May 8 (Reuters) - King Pharmaceuticals Inc posted a 24 percent drop in first-quarter profit on Thursday as sales of its Altace blood-pressure drug plunged due to competition from generics.

Drug company Lupin Ltd on Thursday said it has won a patent litigation in the US on blood pressure drug Altace against King Pharmaceuticals and Sanofi- Aventis, paving the way for the firm to launch ...